GlassScriptPhysician profile
Sara P Moore
NPI 1093266520
$7,138.20
in general payments reported to CMS, 2019-2025
41 companies · $989 in 2025
The $989 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,691 · 2022: $1,552 · 2023: $1,731 · 2024: $1,175 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,894.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,045.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $729.02 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $667.70 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $645.09 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $523.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $509.86 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.81 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $336.51 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $256.78 | 2021-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Pfizer INC. | $206.02 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.62 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.91 | 2021-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $124.34 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $109.92 | 2022 | |
| Axsome Therapeutics, INC. | $108.90 | 2023-2025 | Auvelity |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $97.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $96.28 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $86.77 | 2021-2024 | Xarelto |
| Corcept Therapeutics | $78.75 | 2024-2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $78.40 | 2022-2025 | Quviviq, Quviviq |
| Dexcom, INC. | $75.54 | 2021-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $72.86 | 2021-2023 | Gvoke Hypopen |
| Amgen INC. | $66.14 | 2024 | Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $63.72 | 2022-2023 | Austedo Xr |
| Amarin Pharma, INC. | $58.77 | 2021 | |
| Eisai INC. | $57.35 | 2021 | |
| Lundbeck LLC | $52.76 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $44.00 | 2021-2023 | |
| Astellas Pharma US INC | $41.57 | 2021-2023 | Veozah |
| Edwards Lifesciences Corporation | $30.35 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Alkermes, INC. | $26.02 | 2025 | Aristada, Lybalvi |
| Inari Medical, INC. | $22.83 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Tris Pharma INC | $21.72 | 2025 | Dyanavel Xr |
| Hikma Pharmaceuticals USA | $21.30 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.30 | 2021 | |
| Dynavax Technologies Corporation | $19.15 | 2023 | Heplisav-B |
| Impel Pharmaceuticals INC. | $15.11 | 2023 | Trudhesa |
| Phadia US INC. | $15.07 | 2021 | |
| Scynexis, INC. | $13.77 | 2022 | |
| Abbott Laboratories | $12.10 | 2022 | |
| Vistapharm, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.